## ICMJE DISCLOSURE FORM

Date:	Nov. 24 <sup>th</sup> , 2021	<u>_</u>			
Your Name:	Chad M. Brumme	ett, M.D.			
Manuscript	Title: Opioid Prescribin	ng and Consumption After Head and Neck Free Flap Reconstruc	ction: What is		
he Evidence for Multimodal Analgesia?					
Manuscript	number (if known):	JOMA-21-19			

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
		Time frame: Since the initial	planning of the work		
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	National Institutes of Health (NIH)  State Funding from Michigan	NIH Funding: National Institute on Drug Abuse (RO1 DA042859  Michigan Department of Health and Human Services		
	Time frame: past 36 months				
2	Grants or contracts from any entity (if not indicated in item #1 above).	xNone			
3	Royalties or licenses	x None			
4	Consulting fees	consultant for companies, foundations, and healthcare organizations	consultant for Heron Therapeutics, Vertex Pharmaceuticals, Alosa Health, and the Benter Foundation		

5	Payment or honoraria for	x None				
	lectures, presentations,					
	speakers bureaus,					
	manuscript writing or					
	educational events					
6	Payment for expert	US healthcare	Expert medical testimony for Opioid-related proceedings			
	testimony	organizations/companies				
7	Support for attending	x None	(already disclosed in relation to consulting fees, above)			
	meetings and/or travel					
8	Patents planned, issued or	x None				
	pending					
9	Participation on a Data	x None				
	Safety Monitoring Board or					
	Advisory Board					
10	Leadership or fiduciary role	x None				
	in other board, society,					
	committee or advocacy					
11	group, paid or unpaid Stock or stock options	x None				
11	Stock of Stock options	xNone				
12	Receipt of equipment,	x None				
	materials, drugs, medical					
	writing, gifts or other					
	services					
13	Other financial or non-	x None				
	financial interests					
Plea	Please summarize the above conflict of interest in the following box:					

Chad M. Brummett, M.D. receives funding from the Michigan Department of Health and Human Services and the National Institute on Drug Abuse (RO1 DA042859). He is also a consultant for Heron Therapeutics, Vertex
Pharmaceuticals, Alosa Health, and the Benter Foundation, and he provides expert medical testimony.

Please place an "X" next to the following statement to indicate your agreement:

\_x\_\_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

## ICMJE DISCLOSURE FORM

Date:	Nov. 24 <sup>th</sup> , 2021					
Your Name:	: Michael J. Brenne	er, M.D.				
Manuscript	Title: Opioid Prescribi	ng and Consumption	n After Head ar	nd Neck Free Flan	p Reconstruction: \	What is
the Eviden	ce for Multimodal Ana	lgesia?				
Manuscript	number (if known):	JOMA-21-19				
related to tl	est of transparency, we a	script. "Related" me	ans any relation	with for-profit or	not-for-profit third	

related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initia	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	xNone	
3	Grants or contracts from any entity (if not indicated in item #1 above).  Royalties or licenses	Time frame: pastx Nonex None	36 months
4	Consulting fees	xNone	

6	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony	x Nonex None			
7	Support for attending meetings and/or travel	_x_ None			
8	Patents planned, issued or pending	xNone	_		
9	Participation on a Data Safety Monitoring Board or Advisory Board	_x_ None			
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	_xNone	_		
11	Stock or stock options	x None			
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	_xNone	_		
13	Other financial or non- financial interests	_xNone			
	Please summarize the above conflict of interest in the following box:  None.				

Please place an "X" next to the following statement to indicate your agreement:

\_x\_\_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

## ICMJE DISCLOSURE FORM

ate: Nov. 24 <sup>th</sup> , 2021
our Name: John D. Cramer, M.D.
lanuscript Title: Opioid Prescribing and Consumption After Head and Neck Free Flap Reconstruction: What is
ne Evidence for Multimodal Analgesia?
lanuscript number (if known): <u>JOMA-21-19</u>

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present	x None	planning of the work
1	manuscript (e.g., funding,	xNone	
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	x None	
	any entity (if not indicated		
_	in item #1 above).	N. N	
3	Royalties or licenses	x None	
4	Consulting fees	x None	
	201134111115 1223		

6	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony	x Nonex None			
7	Support for attending meetings and/or travel	_x_ None			
8	Patents planned, issued or pending	xNone	_		
9	Participation on a Data Safety Monitoring Board or Advisory Board	_x_ None			
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	_xNone	_		
11	Stock or stock options	x None			
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	_xNone	_		
13	Other financial or non- financial interests	_xNone			
	Please summarize the above conflict of interest in the following box:  None.				

Please place an "X" next to the following statement to indicate your agreement:

\_x\_\_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.